Drugs / SAR440894
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04441905 | Oct 2020 → Aug 2024 | chikungunya | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAR440894 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04441905 ↗ |
| Modality | Monoclonal antibody | “SAR440894 monoclonal antibody (IgG1)” NCT04441905 ↗ |
| Route | Intravenous | “One time 60-minute IV infusion of SAR440894 monoclonal antibody (IgG1) directed against the E2 envelope protein of chikungunya virus” NCT04441905 ↗ |